Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Daptomycin: a comparison of two intravenous formulations.

Frankenfeld C, Mittal S, Melendez Y, Mendez-Vigo L, Lamp KC, Keller KN, Bertolami SR.

Drug Des Devel Ther. 2018 Jun 29;12:1953-1958. doi: 10.2147/DDDT.S167010. eCollection 2018. Review.

2.

A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin.

Hermsen ED, Mendez-Vigo L, Berbari EF, Chung T, Yoon M, Lamp KC.

BMC Infect Dis. 2016 Jun 24;16:310. doi: 10.1186/s12879-016-1590-3.

3.

Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.

Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, Bauer K, Goff DA, Adamson R, Leuthner K, Virata MD, McKinnell JA, Chaudhry SB, Eskandarian R, Lodise T, Reyes K, Zervos MJ.

Clin Ther. 2016 Jan 1;38(1):16-30. doi: 10.1016/j.clinthera.2015.09.017. Epub 2015 Nov 14.

PMID:
26585355
4.

Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Culshaw D, Lamp KC, Yoon MJ, Lodise TP.

Diagn Microbiol Infect Dis. 2015 Oct;83(2):193-7. doi: 10.1016/j.diagmicrobio.2015.06.003. Epub 2015 Jun 11.

5.

Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia.

Moise PA, Sakoulas G, McKinnell JA, Lamp KC, DePestel DD, Yoon MJ, Reyes K, Zervos MJ.

Clin Ther. 2015 Jul 1;37(7):1443-1453.e2. doi: 10.1016/j.clinthera.2015.04.008. Epub 2015 May 15.

PMID:
25982687
6.

Daptomycin experience in patients with human immunodeficiency virus and resistant gram-positive infections.

Slim J, Jimenez H, Culshaw D, Patel H, Lamp KC.

J Int Assoc Provid AIDS Care. 2015 May-Jun;14(3):202-6. doi: 10.1177/2325957414553840. Epub 2014 Oct 15.

PMID:
25320146
7.

Breaking down the barriers: challenges with development and implementation of an industry-sponsored antimicrobial stewardship data collection and analysis tool.

Hermsen ED, McDaneld PM, Eiland EH 3rd, Destache CJ, Lusardi K, Estrada SJ, Mercier RC, DePestel DD, Lamp KC, Anderson E, Chung TJ, McKinnon PS.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S179-84. doi: 10.1093/cid/ciu539.

PMID:
25261545
8.

Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter.

DePestel DD, Eiland EH 3rd, Lusardi K, Destache CJ, Mercier RC, McDaneld PM, Lamp KC, Chung TJ, Hermsen ED.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S154-61. doi: 10.1093/cid/ciu548.

PMID:
25261542
9.

Outcomes and metrics for antimicrobial stewardship: survey of physicians and pharmacists.

Bumpass JB, McDaneld PM, DePestel DD, Lamp KC, Chung TJ, McKinnon PS, Crompton MG, Hermsen ED.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S108-11. doi: 10.1093/cid/ciu545.

PMID:
25261537
10.

Daptomycin for methicillin-resistant Staphylococcus aureus diabetic foot infections.

Joseph WS, Quast T, Cogo A, Crompton MG, Yoon MJ, Lamp KC, Culshaw D, Chaves RL.

J Am Podiatr Med Assoc. 2014 Mar;104(2):159-68. doi: 10.7547/0003-0538-104.2.159.

PMID:
24725036
11.

Daptomycin use in neutropenic patients with documented gram-positive infections.

Rolston KV, Besece D, Lamp KC, Yoon M, McConnell SA, White P.

Support Care Cancer. 2014 Jan;22(1):7-14. doi: 10.1007/s00520-013-1947-8. Epub 2013 Aug 24.

PMID:
23975231
12.

Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experience.

Rege S, Mohr J, Lamp KC, Yoon M, Lindfield KC.

Int J Antimicrob Agents. 2013 May;41(5):421-5. doi: 10.1016/j.ijantimicag.2012.12.008. Epub 2013 Feb 5.

PMID:
23394685
13.

Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant ╬▓-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A.

Antimicrob Agents Chemother. 2013 Mar;57(3):1192-200. doi: 10.1128/AAC.02192-12. Epub 2012 Dec 17.

14.

Daptomycin experience in critical care patients: results from a registry.

Brown JE, Fominaya C, Christensen KJ, McConnell SA, Lamp KC.

Ann Pharmacother. 2012 Apr;46(4):495-502. doi: 10.1345/aph.1Q490. Epub 2012 Mar 27.

PMID:
22454446
15.

Safety of daptomycin in patients receiving hemodialysis.

Mueller BA, Crompton JA, Donovan BJ, Yankalev S, Lamp KC.

Pharmacotherapy. 2011 Jul;31(7):665-72. doi: 10.1592/phco.31.7.665.

16.

Safety and clinical outcomes among older adults receiving daptomycin therapy: Insights from a patient registry.

DePestel DD, Hershberger E, Lamp KC, Malani PN.

Am J Geriatr Pharmacother. 2010 Dec;8(6):551-61. doi: 10.1016/S1543-5946(10)80004-2.

PMID:
21356504
17.

Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.

Crompton JA, North DS, Yoon M, Steenbergen JN, Lamp KC, Forrest GN.

J Antimicrob Chemother. 2010 Aug;65(8):1784-91. doi: 10.1093/jac/dkq200. Epub 2010 Jun 16.

18.

Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry.

Rolston KV, McConnell SA, Brown J, Lamp KC.

Clin Adv Hematol Oncol. 2010 Apr;8(4):249-56, 90.

PMID:
20505648
20.

Retrospective review of the use of daptomycin for diabetic foot infections.

Johnson K, Lamp KC, Friedrich LV.

J Wound Care. 2009 Sep;18(9):396-400.

PMID:
19789477
21.

Daptomycin for the treatment of surgical site infections.

Chamberlain RS, Culshaw DL, Donovan BJ, Lamp KC.

Surgery. 2009 Aug;146(2):316-24. doi: 10.1016/j.surg.2009.03.037.

PMID:
19628091
22.

Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.

Crompton JA, North DS, McConnell SA, Lamp KC.

J Chemother. 2009 Aug;21(4):414-20.

PMID:
19622460
23.

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC.

Ann Pharmacother. 2009 Jul;43(7):1211-9. doi: 10.1345/aph.1M085. Epub 2009 Jul 7.

PMID:
19584384
24.

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

Mohr JF, Friedrich LV, Yankelev S, Lamp KC.

Int J Antimicrob Agents. 2009 Jun;33(6):543-8. doi: 10.1016/j.ijantimicag.2008.12.007. Epub 2009 Feb 6.

PMID:
19201165
25.

Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis.

Forrest GN, Donovan BJ, Lamp KC, Friedrich LV.

Ann Pharmacother. 2008 Feb;42(2):213-7. doi: 10.1345/aph.1K535. Epub 2008 Jan 22.

PMID:
18212253
26.

Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.

Owens RC Jr, Lamp KC, Friedrich LV, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S6-12.

PMID:
17904950
27.

Cubicin Outcomes Registry and Experience (CORE) methodology.

Rolston KV, Segreti J, Lamp KC, Friedrich LV.

Am J Med. 2007 Oct;120(10 Suppl 1):S4-5.

PMID:
17904949
28.

Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.

Levine DP, Lamp KC.

Am J Med. 2007 Oct;120(10 Suppl 1):S28-33.

PMID:
17904948
29.

Daptomycin in the treatment of bacteremia.

Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S21-7.

PMID:
17904947
30.

Clinical experience with daptomycin for the treatment of patients with osteomyelitis.

Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S13-20.

PMID:
17904946
31.

Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study.

Holtom PD, Zalavras CG, Lamp KC, Park N, Friedrich LV.

Clin Orthop Relat Res. 2007 Aug;461:35-9.

PMID:
17549028
34.

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Lamp KC, Freeman CD, Klutman NE, Lacy MK.

Clin Pharmacokinet. 1999 May;36(5):353-73. Review.

PMID:
10384859
35.

Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement.

Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH.

Ann Pharmacother. 1998 Oct;32(10):1004-7.

PMID:
9793589
37.

Metronidazole. A therapeutic review and update.

Freeman CD, Klutman NE, Lamp KC.

Drugs. 1997 Nov;54(5):679-708. Review.

PMID:
9360057
38.

Low pharmacist counseling rates in the Kansas City, Missouri, metropolitan area.

Fritsch MA, Lamp KC.

Ann Pharmacother. 1997 Sep;31(9):984-91.

PMID:
9296236
39.
40.

Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus.

Stanley D, McGrath BJ, Lamp KC, Rybak MJ.

Pharmacotherapy. 1994 Jan-Feb;14(1):35-9.

PMID:
8159599
41.

Prospective evaluation of red man syndrome in patients receiving vancomycin.

O'Sullivan TL, Ruffing MJ, Lamp KC, Warbasse LH, Rybak MJ.

J Infect Dis. 1993 Sep;168(3):773-6.

PMID:
8354921
43.

Comparing Pneumocystis carinii pneumonia prophylactic regimens.

Khaliq Y, Lamp KC.

Arch Intern Med. 1993 Mar 22;153(6):782-3. No abstract available.

PMID:
8447720
45.

Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.

McGrath BJ, Bailey EM, Lamp KC, Rybak MJ.

Antimicrob Agents Chemother. 1992 Dec;36(12):2741-6. Erratum in: Antimicrob Agents Chemother 1993 Apr;37(4):930.

46.

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Lamp KC, Rybak MJ, Bailey EM, Kaatz GW.

Antimicrob Agents Chemother. 1992 Dec;36(12):2709-14. Erratum in: Antimicrob Agents Chemother 1993 Apr;37(4):930.

47.

CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Kaatz GW, Seo SM, Lamp KC, Bailey EM, Rybak MJ.

Antimicrob Agents Chemother. 1992 Jun;36(6):1192-7.

48.
49.

Ofloxacin clinical pharmacokinetics.

Lamp KC, Bailey EM, Rybak MJ.

Clin Pharmacokinet. 1992 Jan;22(1):32-46. Review.

PMID:
1559306
50.

Indomethacin for prevention of neonatal intraventricular hemorrhage.

Lamp KC, Reynolds MS.

DICP. 1991 Dec;25(12):1344-8. Review.

PMID:
1815433

Supplemental Content

Support Center